{"id":"https://openalex.org/W2013366147","doi":"https://doi.org/10.1002/j.1552-4604.1984.tb02761.x","title":"Oxaprozin Dose Proportionality","display_name":"Oxaprozin Dose Proportionality","publication_year":1984,"publication_date":"1984-11-12","ids":{"openalex":"https://openalex.org/W2013366147","doi":"https://doi.org/10.1002/j.1552-4604.1984.tb02761.x","mag":"2013366147","pmid":"https://pubmed.ncbi.nlm.nih.gov/6511991"},"language":"en","primary_location":{"id":"doi:10.1002/j.1552-4604.1984.tb02761.x","doi":"https://doi.org/10.1002/j.1552-4604.1984.tb02761.x","is_oa":false,"landing_page_url":"https://doi.org/10.1002/j.1552-4604.1984.tb02761.x","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109207812","display_name":"Soong T. Chiang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"SOONG T. CHIANG","raw_affiliation_strings":["Philadelphia, Penn., and Miami, Fla"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Philadelphia, Penn., and Miami, Fla","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061427649","display_name":"Kenneth C. Lasseter","orcid":"https://orcid.org/0000-0001-8175-2199","observed_orcids":["https://orcid.org/0000-0001-8175-2199"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"KENNETH C. LASSETER","raw_affiliation_strings":["Philadelphia, Penn., and Miami, Fla","Wyeth Laboratories, Philadelphia, Penn.; and University of Miami, School of Medicine and Clinical Pharmacology Associates, Miami, Fla","University of Miami, School of Medicine and Clinical Pharmacology Associates, Miami, Fla","Wyeth Laboratories, Philadelphia, Penn"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Philadelphia, Penn., and Miami, Fla","institution_ids":[]},{"raw_affiliation_string":"Wyeth Laboratories, Philadelphia, Penn.; and University of Miami, School of Medicine and Clinical Pharmacology Associates, Miami, Fla","institution_ids":["https://openalex.org/I145608581"]},{"raw_affiliation_string":"University of Miami, School of Medicine and Clinical Pharmacology Associates, Miami, Fla","institution_ids":["https://openalex.org/I145608581"]},{"raw_affiliation_string":"Wyeth Laboratories, Philadelphia, Penn","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090485785","display_name":"Eugene R. Fluck","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"EUGENE R. FLUCK","raw_affiliation_strings":["Philadelphia, Penn., and Miami, Fla"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Philadelphia, Penn., and Miami, Fla","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109861425","display_name":"Frank W. Janssen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"FRANK W. JANSSEN","raw_affiliation_strings":["Philadelphia, Penn., and Miami, Fla"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Philadelphia, Penn., and Miami, Fla","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"DODDA LEELAVATHI","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"DODDA LEELAVATHI","raw_affiliation_strings":["Philadelphia, Penn., and Miami, Fla"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Philadelphia, Penn., and Miami, Fla","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052969885","display_name":"Jerome A. Hubsher","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JEROME A. HUBSHER","raw_affiliation_strings":["Philadelphia, Penn., and Miami, Fla"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Philadelphia, Penn., and Miami, Fla","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5109207812"],"corresponding_institution_ids":[],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":1.5208,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.78615657,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"11","first_page":"515","last_page":"522"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7875999808311462,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7875999808311462,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11908","display_name":"Protein Interaction Studies and Fluorescence Analysis","score":0.07999999821186066,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.021299999207258224,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oxaprozin","display_name":"oxaprozin","score":1.0},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.9940000176429749},{"id":"https://openalex.org/keywords/protein-binding","display_name":"protein binding","score":0.7649999856948853},{"id":"https://openalex.org/keywords/unbound-drug-fraction","display_name":"unbound drug fraction","score":0.6330000162124634},{"id":"https://openalex.org/keywords/intrinsic-clearance","display_name":"intrinsic clearance","score":0.9919999837875366},{"id":"https://openalex.org/keywords/plasma-protein-binding","display_name":"plasma protein binding","score":0.5080000162124634},{"id":"https://openalex.org/keywords/linear-pharmacokinetics","display_name":"linear pharmacokinetics","score":0.675000011920929},{"id":"https://openalex.org/keywords/nonlinear-pharmacokinetics","display_name":"nonlinear pharmacokinetics","score":0.5289999842643738},{"id":"https://openalex.org/keywords/nonsteroidal-anti-inflammatory-drugs","display_name":"nonsteroidal anti-inflammatory drugs","score":0.3569999933242798}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6610011458396912},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.6147843599319458},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5666759610176086},{"id":"https://openalex.org/C3020079912","wikidata":"https://www.wikidata.org/wiki/Q3918988","display_name":"Plasma concentration","level":2,"score":0.5419550538063049},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.4498332440853119},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44526806473731995},{"id":"https://openalex.org/C3018403923","wikidata":"https://www.wikidata.org/wiki/Q1163287","display_name":"Plasma clearance","level":3,"score":0.4372677206993103},{"id":"https://openalex.org/C3019361228","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral dose","level":3,"score":0.42111936211586},{"id":"https://openalex.org/C2991747820","wikidata":"https://www.wikidata.org/wiki/Q1896673","display_name":"Plasma volume","level":2,"score":0.4197234511375427},{"id":"https://openalex.org/C110121322","wikidata":"https://www.wikidata.org/wiki/Q865811","display_name":"Distribution (mathematics)","level":2,"score":0.41747626662254333},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23705223202705383},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.16358357667922974},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.08676391839981079},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000077431","descriptor_name":"Oxaprozin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007700","descriptor_name":"Kinetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011422","descriptor_name":"Propionates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011422","descriptor_name":"Propionates","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/j.1552-4604.1984.tb02761.x","doi":"https://doi.org/10.1002/j.1552-4604.1984.tb02761.x","is_oa":false,"landing_page_url":"https://doi.org/10.1002/j.1552-4604.1984.tb02761.x","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:6511991","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/6511991","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W74649421","https://openalex.org/W186444755","https://openalex.org/W1958358203","https://openalex.org/W1974378302","https://openalex.org/W1996799113","https://openalex.org/W1997900059","https://openalex.org/W2004412195","https://openalex.org/W2009244186","https://openalex.org/W2027519918","https://openalex.org/W2036736656","https://openalex.org/W2036748228","https://openalex.org/W2036780691","https://openalex.org/W2055769836","https://openalex.org/W2057511933","https://openalex.org/W2059973305","https://openalex.org/W2086682470","https://openalex.org/W2088577015","https://openalex.org/W2092024303","https://openalex.org/W2143312213","https://openalex.org/W2228955563","https://openalex.org/W2336259172","https://openalex.org/W2399866574","https://openalex.org/W2412032634","https://openalex.org/W2505677286","https://openalex.org/W4285719527","https://openalex.org/W4290665038"],"related_works":["https://openalex.org/W1988087731","https://openalex.org/W2418355886","https://openalex.org/W1973237728","https://openalex.org/W1974378302","https://openalex.org/W2004412195","https://openalex.org/W2130224702","https://openalex.org/W2150215646","https://openalex.org/W1997516444","https://openalex.org/W7096870924","https://openalex.org/W2136431378"],"abstract_inverted_index":{"Twelve":[0],"normal":[1],"subjects":[2],"each":[3],"received":[4],"single":[5],"300-,":[6],"600-,":[7],"and":[8,36,99,110,171,181],"1200-mg":[9],"oral":[10],"doses":[11],"of":[12,38,52,91,104,107],"oxaprozin":[13,54,148,163],"according":[14],"to":[15,29,73,86,100,153],"a":[16,96,174],"three-period":[17],"crossover":[18],"design.":[19],"Total":[20,33],"drug":[21,93,184],"plasma":[22,56,62,94,164],"concentrations":[23],"did":[24],"not":[25],"increase":[26],"in":[27,55,128,186],"proportion":[28],"the":[30,88,102,125,129,167,178,182],"dose":[31,169,179],"administered.":[32],"clearance":[34,112],"(CIo)":[35],"volume":[37,106],"distribution":[39,108],"(Vd)":[40],"increased":[41,65,122],"with":[42,60,123,144],"dose,":[43,98,124],"though":[44,120],"elimination":[45],"t1":[46],"2":[47],"remained":[48],"unchanged.":[49],"The":[50],"fraction":[51],"unbound":[53,92,105,147,162,183],"(fup)":[57],"varied":[58],"linearly":[59],"total":[61],"concentration:":[63],"it":[64],"from":[66],"0.068":[67],"per":[68,75,134],"cent":[69,76],"at":[70,77],"10":[71],"micrograms/ml":[72],"0.180":[74],"170":[78],"micrograms/ml.":[79],"A":[80],"parameter":[81],"fup":[82,121],"was":[83,136,173],"therefore":[84],"introduced":[85],"express":[87],"average":[89],"degree":[90],"for":[95],"given":[97,168],"allow":[101],"calculation":[103],"(Vdu)":[109],"intrinsic":[111],"(CIi)":[113],"as":[114],"if":[115],"binding":[116,127,157],"were":[117],"constant.":[118],"Even":[119],"overall":[126],"body":[130],"(fub":[131],"approximately":[132],"0.52":[133],"cent)":[135],"relatively":[137],"stable.":[138],"Neither":[139],"Vdu":[140],"nor":[141],"CIi":[142],"changed":[143],"dose;":[145],"hence,":[146],"kinetics":[149],"can":[150],"be":[151,154],"considered":[152],"linear.":[155],"Protein":[156],"had":[158],"no":[159],"effect":[160],"on":[161],"levels":[165],"within":[166],"range,":[170],"there":[172],"one-to-one":[175],"proportionality":[176],"between":[177],"administered":[180],"concentration":[185],"plasma.":[187]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}